Grant Vallance

494 total citations
14 papers, 115 citations indexed

About

Grant Vallance is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Grant Vallance has authored 14 papers receiving a total of 115 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hematology, 7 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in Grant Vallance's work include Multiple Myeloma Research and Treatments (8 papers), Protein Degradation and Inhibitors (5 papers) and Peptidase Inhibition and Analysis (4 papers). Grant Vallance is often cited by papers focused on Multiple Myeloma Research and Treatments (8 papers), Protein Degradation and Inhibitors (5 papers) and Peptidase Inhibition and Analysis (4 papers). Grant Vallance collaborates with scholars based in United Kingdom, Brazil and Switzerland. Grant Vallance's co-authors include Jamie Bentham, Julia Clark, Karthik Ramasamy, Jaimal Kothari, Matthew Jenner, Efstathios Kastritis, Benjamin Brown, Ioannis Ntanasis‐Stathopoulos, Jiří Minařík and Maria Kotsopoulou and has published in prestigious journals such as Blood, PLoS ONE and Annals of Oncology.

In The Last Decade

Grant Vallance

12 papers receiving 112 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Grant Vallance United Kingdom	6	55	44	40	35	30	14	115
Manita Bremmers Netherlands	5	79 1.4×	81 1.8×	24 0.6×	19 0.5×	8 0.3×	8	184
Maria Luisa Pérez‐Saldívar Mexico	8	43 0.8×	24 0.5×	32 0.8×	103 2.9×	7 0.2×	15	182
Beth Hazel Canada	6	64 1.2×	31 0.7×	53 1.3×	26 0.7×	18 0.6×	6	168
Gabriela Rodríguez Macias Spain	4	24 0.4×	15 0.3×	16 0.4×	28 0.8×	7 0.2×	9	71
Felice Bombaci France	4	93 1.7×	24 0.5×	9 0.2×	14 0.4×	11 0.4×	13	129
Kelda M. Gardner United States	6	126 2.3×	79 1.8×	28 0.7×	50 1.4×	4 0.1×	20	168
Liliana Velasco‐Hidalgo Mexico	7	21 0.4×	42 1.0×	25 0.6×	74 2.1×	14 0.5×	25	147
Patricia Valverde United States	6	25 0.5×	51 1.2×	19 0.5×	88 2.5×	10 0.3×	8	157
A. H. Partridge United States	6	9 0.2×	115 2.6×	14 0.3×	32 0.9×	18 0.6×	17	155
Laura Labonté Canada	5	45 0.8×	20 0.5×	15 0.4×	21 0.6×	8 0.3×	12	181

Countries citing papers authored by Grant Vallance

Since Specialization

Citations

This map shows the geographic impact of Grant Vallance's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Grant Vallance with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Grant Vallance more than expected).

Fields of papers citing papers by Grant Vallance

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Grant Vallance. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Grant Vallance. The network helps show where Grant Vallance may publish in the future.

Co-authorship network of co-authors of Grant Vallance

This figure shows the co-authorship network connecting the top 25 collaborators of Grant Vallance. A scholar is included among the top collaborators of Grant Vallance based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Grant Vallance. Grant Vallance is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Watson, Robert, Orion Tong, Chelsea Taylor, et al.. (2023). 135P The lymphocyte stability index (LSI) forms a pan-cancer peripheral biomarker for overall survival post initiation of immune checkpoint blockade (ICB). Annals of Oncology. 34. S235–S235. 1 indexed citations

Tsiachristas, Apostolos, Grant Vallance, Rositsa Koleva‐Kolarova, et al.. (2022). Can upfront DPYD extended variant testing reduce toxicity and associated hospital costs of fluoropyrimidine chemotherapy? A propensity score matched analysis of 2022 UK patients. BMC Cancer. 22(1). 458–458. 7 indexed citations

Kishore, Bhuvan, et al.. (2022). Panobinostat in combination with bortezomib and dexamethasone in multiply relapsed and refractory myeloma; UK routine care cohort. PLoS ONE. 17(7). e0270854–e0270854. 4 indexed citations

Anderson, Laura N., et al.. (2022). Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series. Hematology. 27(1). 204–207. 5 indexed citations

Vallance, Grant, et al.. (2021). Daratumumab Monotherapy for Heavily Pre-treated and Refractory Myeloma: Results from a UK Multicentre Real World Cohort. Journal of Oncology Pharmacy Practice. 29(2). 299–304. 2 indexed citations

Quek, Lynn, Itamar S Santos, Juan Luiz Coelho‐Silva, et al.. (2020). Integrating clinical features with genetic factors enhances survival prediction for adults with acute myeloid leukemia. Blood Advances. 4(10). 2339–2350. 10 indexed citations

Coelho‐Silva, Juan Luiz, Grant Vallance, Diego A. Pereira‐Martins, et al.. (2020). A multicenter comparative acute myeloid leukemia study: can we explain the differences in the outcomes in resource-constrained settings?. Leukemia & lymphoma. 62(1). 147–157. 6 indexed citations

Sharpley, Faye, Grant Vallance, Toby A. Eyre, et al.. (2020). Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients. PLoS ONE. 15(2). e0229469–e0229469. 4 indexed citations

Terpos, Evangelos, Karthik Ramasamy, Jiří Minařík, et al.. (2020). Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. Annals of Hematology. 99(5). 1049–1061. 26 indexed citations

10.

Kishore, Bhuvan, Matthew Jenner, Kevin Boyd, et al.. (2020). Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (≥2nd relapse) refractory myeloma: a multicenter real world UK experience. Leukemia & lymphoma. 62(6). 1396–1404. 5 indexed citations

11.

Sharpley, Faye, Grant Vallance, Fotios Panitsas, et al.. (2020). Myeloma clinical outcomes following the first wave of COVID‐19: results from the Thames Valley Cancer Alliance (UK). British Journal of Haematology. 192(6). e136–e139.

12.

Quek, Lynn, Juan Luiz Coelho‐Silva, Diego A. Pereira‐Martins, et al.. (2019). Combining Clinical Features with Genetic Factors Improves Survival Prediction for Adults with Acute Myeloid Leukemia: Validation of a New Score System in 3 Cohorts. Blood. 134(Supplement_1). 2602–2602.

13.

Vallance, Grant, et al.. (2018). Clinical outcomes of bortezomib-based therapy in myeloma. PLoS ONE. 13(12). e0208920–e0208920. 5 indexed citations

14.

Bentham, Jamie, et al.. (1999). Students conducting consultations in general practice and the acceptability to patients. Medical Education. 33(9). 686–687. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact